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Abstract
Idiopathic pulmonary fibrosis (IPF) remains exactly that. The disease originates from an unknown
cause, and little is known about the mechanisms of pathogenesis. While the disease is likely multi-
factorial, evidence is accumulating to implicate viruses as co-factors (either as initiating or
exacerbating agents) of fibrotic lung disease. This review summarizes the available clinical and
experimental observations that form the basis for the hypothesis that viral infections may augment
fibrotic responses. We review the data suggesting a link between hepatitis C virus, adenovirus,
human cytomegalovirus and, in particular, the Epstein-Barr gammaherpesvirus, in IPF. In addition,
we highlight the recent associations made between gammaherpesvirus infection and lung fibrosis in
horses and discuss the various murine models that have been used to investigate the contribution
of gammaherpesviruses to fibrotic progression. We review the work demonstrating that
gammaherpesvirus infection of Th2-biased mice leads to multi-organ fibrosis and highlight studies
showing that gammaherpesviral infections of mice either pre- or post-fibrotic challenge can
augment the development of fibrosis. Finally, we discuss potential mechanisms whereby viral
infections may amplify the development of fibrosis. While none of these studies prove causality, we
believe the evidence suggests that viral infections should be considered as potential initiators or
exacerbating agents in at least some cases of IPF and thereby justify further study.
Background
Idiopathic pulmonary fibrosis (IPF) is a progressive inter-
stitial lung disease that severely compromises pulmonary
function [1]. IPF likely results from an abnormal healing
response to injury of the alveolar surface, and develop-
ment of the disease is characterized by fibroblast hyper-
plasia and progressive collagen deposition that effaces
normal lung tissue [2]. The median survival time for
patients with IPF is 3 years from the time of diagnosis, and
there is currently no effective treatment [3].
Fibrotic lung disease likely results from an inciting injuri-
ous event within the lung. Although the precise temporal
sequence of events and mechanisms of disease are not
understood, several common pathobiological characteris-
tics are recognized. These include damage and loss of type
I alveolar epithelial cells followed by hyperplastic expan-
sion of type II cells [4]; variable chronic inflammatory cell
infiltration [5]; a predominant T helper (Th)2 cytokine
profile [6]; induction of pro-inflammatory cytokines,
such as interleukin (IL)-8 and tumor necrosis factor
(TNF)α [7,8]; induction of fibroblast growth factors, such
as basic fibroblast growth factor and platelet-derived
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such as transforming growth factor (TGF)-β1 [6,10]; an
altered fibroblast phenotype characterized by exuberant
proliferation and the transition to α-smooth muscle actin-
positive myofibroblasts [11]; excessive deposition of
extracellular matrix proteins [12]; derangements in eicosa-
noid synthesis, including increased leukotriene synthesis
and diminished prostaglandin production [13,14];
diminished activation of plasminogen and altered coagu-
lation cascades [15,16]; and recruitment of bone-marrow
derived fibrocytes [17-19].
Despite ongoing research driven by the need for therapy,
the initiating or injurious agents are unknown, and it is
not understood why the fibrosis is dysregulated and pro-
gressive [20]. It is likely that the disease initiates with
some form of alveolar epithelial cell injury. This could be
in the form of inhaled toxins or due to genetic abnormal-
ities, such as mutations in telomerase or surfactant pro-
tein C [21-25], but more research is needed to fully
understand the etiology of lung fibrosis. The natural his-
tory of the disease can take at least two forms. Patients can
experience a gradually progressive disease, characterized
by steady worsening of symptoms, lung function and gas
exchange [26,27] or they can experience an acute respira-
tory deterioration termed an acute exacerbation noted by
rapid worsening of symptoms over a short time frame
(usually less than 1 month) [28]. Acute exacerbations can
have extremely high mortality rates (reviewed in [28]).
Both the development of IPF and the onset of acute exac-
erbations are idiopathic but may involve toxic exposures,
genetics, aspiration, disordered coagulation and compli-
cations of comorbidities [28]. An emerging hypothesis is
that occult infections may play a pathogenic role as co-fac-
tors for the development of IPF or acute exacerbations. It
is possible that the chronic presence of an inflammatory
agent like a virus in a genetically susceptible host disrupts
the normal healing response, thus making the lung highly
susceptible to a separate injurious trigger. Viruses are
intriguing candidates for a role in IPF because of their
ubiquitous incidence in humans and because of the
nature of their lifecycle. Some viruses exist as an antigenic
stimulant in the epithelial cells of the lung in an actively
replicating and potentially injurious lytic phase while
other viruses persist in a latent phase for an entire lifetime.
It is interesting to note that some viruses, such as Epstein-
Barr virus (EBV), which has been linked to IPF, are known
to infect most people at some point in their life [29]. This
raises the interesting question of why some people may
develop IPF in response to this infection while others may
not. Clearly, there is no easy answer, but it is likely that
differential host responses to the virus may alter the
pathogenesis. For instance, latent EBV infection is most
often found in B cells [29]; however, in patients with IPF,
EBV can be found in lung tissue, including epithelial cells
[30,31]. Alternatively, stress, drug exposures or immuno-
deficiency may be responsible for viral reactivation in
some patients, but not others. In this review, we discuss
the available evidence that hepatitis C, adenovirus and
cytomegalovirus infections are found in association with
IPF. By far the most compelling evidence for a viral co-fac-
tor in IPF comes from studies of the association between
the gammaherpesvirus, EBV, and IPF. The data regarding
the role of EBV in IPF will be discussed last and will then
be followed by a discussion of animal models that dem-
onstrate a pro-fibrotic role for gammaherpesvirus infec-
tions.
Human studies that have suggested a link between IPF and 
particular viral infections
Hepatitis C
Two studies have suggested a link between infection with
the hepatitis C virus (HCV) and IPF. HCV is a small, envel-
oped, positive-sense single-stranded RNA virus in the Fla-
vivirus family [32]. Replication within hepatocytes causes
a form of hepatitis, but the virus may be able to enter
other cell types [33]. Ueda et al. [34] were able to show a
significant difference between the percentage of Japanese
IPF patients who had serum antibodies to HCV (28.8%)
and the corresponding percentage of control subjects
(3.66%). A subsequent Italian study confirmed that 13%
of patients with IPF were seropositive for HCV [35]. In a
control group of 4,614 blood donors, the prevalence of
HCV antibodies was lower (0.3%). However, in a control
group of 130 patients with non-interstitial lung disease,
HCV antibody prevalence was 6.1%. While this was signif-
icantly higher than the blood donor group, the incidence
of HCV in patients with non-interstitial lung disease and
IPF were not statistically different. It should also be noted
that a British study failed to find an association between
IPF and HCV [36]. One possible explanation for these
findings is that there may be geographical differences in
the prevalence of HCV infection, as the infection is more
commonly seen in Japan and Mediterranean countries
than it is in northern Europe [35]. Given that HCV is not
known to replicate in the lung, it is not clear whether these
associations suggest that HCV is pathogenic in IPF, or
rather if they indicate that IPF patients develop HCV cross-
reactive antibodies. Thus, further research in this area will
be needed.
Adenovirus
Human adenoviruses have been suggested as etiological
co-factors in the progression of interstitial lung disease
[37-39]. Adenoviruses are medium-sized, non-enveloped,
icosahedral, double-stranded DNA viruses. They are rela-
tively resistant to chemical and physical agents, and as a
result, they can remain infectious outside of the body for
extended periods of time. Adenovirus infections typically
cause respiratory symptoms and can be shed for long peri-Page 2 of 11
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ined 19 patients with IPF, 10 patients with interstitial
pneumonia associated with collagen vascular disease, and
20 patients with sarcoidosis using nested PCR and in situ
hybridization for the adenovirus gene product E1A. E1A
DNA was present in 3 out of 19 (16%) cases of IPF, in 5
of 10 (50%) cases of interstitial pneumonia associated
with collagen vascular disease, and in 2 of 20 (10%) cases
of sarcoidosis [38]. While these data are not suggestive of
a correlation between adenovirus infection and pulmo-
nary fibrosis, Kuwano et al. found that the incidence of
E1A DNA was considerably higher in patients who had
been treated with corticosteroids (67%) compared to
those patients left untreated (10%). This finding raises the
interesting possibility that corticosteroids, a common
therapy for IPF, may make patients more susceptible to
adenovirus infection or reactivation from latency. How-
ever, studies investigating the titer of anti-adenoviral IgG
in IPF patients have failed to demonstrate an elevation
above normal [40]. Despite this, it is important to note
that E1A has been shown to upregulate production of the
pro-fibrotic mediator, TGF-β, and to induce lung epithe-
lial cells to express mesenchymal markers [41]. This
mechanism has been implicated in the architectural
remodeling that occurs in chronic obstructive pulmonary
disease. It is possible that a similar mechanism could con-
tribute to extracellular matrix deposition and remodeling
in those IPF patients who may also have adenovirus infec-
tions.
It is also conceivable that adenovirus infections could
serve as exacerbating agents for patients with established
lung fibrosis, although it is difficult to determine the fre-
quency of this happening from published clinical litera-
ture. Furthermore, recent studies using an animal model
of fluorescein isothiocyante (FITC)-induced fibrosis were
unable to demonstrate significant exacerbation of FITC-
fibrosis within the first 7 days post-mouse adenoviral
infection [42]. One note of caution in the interpretation
of these experiments, however, is that human and mouse
adenoviruses do show different tropisms, with human
adenoviruses being predominantly respiratory pathogens.
Interestingly, in studies using the same murine model, a
gammaherpesvirus was able to augment FITC-induced
fibrosis (see below). Whether the difference in the ability
of mouse adenovirus and mouse gammaherpesvirus to
exacerbate FITC-fibrosis represents differences in cell tro-
pisms, inflammatory response or mediators released is
unknown.
Human cytomegalovirus
Human cytomegalovirus (HCMV), a betaherpesvirus, is a
widespread opportunistic pathogen that persists in
healthy individuals but normally only causes clinical
manifestations in immune-compromised individuals
[43]. HCMV infects the respiratory tract, and it has been
evaluated with regards to IPF. Dworniczak et al. [44] stud-
ied 16 patients, newly diagnosed with IPF and never
treated, compared to 16 adult healthy volunteers. HCMV
DNA copy number in broncho-alveolar lavage (BAL) cells,
blood leukocytes, and serum was calculated by real-time
PCR, and the prevalence of the HCMV DNA positive sub-
jects in the patient group (75%) did not differ signifi-
cantly from the prevalence of positive subjects in the
control group (69%). IPF patients did show significantly
higher DNA copy numbers in their blood compared to
controls, however [44]. Also, the viral copy number in the
BAL cells of both IPF patients and healthy volunteers was
elevated relative to respective viral copy numbers in blood
leukocytes, suggesting an important role for the lungs
(perhaps as a viral reservoir) in the pathobiology of
HCMV. Consistent with this idea, a subsequent study by
Tang et al. [45] did note higher levels of HCMV DNA in
IPF lung tissue compared to control samples. Similarly, in
a study by Yonemaru et al. [40], HCMV IgG and comple-
ment fixation titers were found to be elevated in the serum
of patients with IPF when compared to several other dis-
ease-specific controls. In a retrospective study of lung
transplant recipients, 102 patients were screened by urine
test for evidence of HCMV infection on the day of trans-
plant. Only five patients were found to be HMCV+ prior
to transplant, and all five of the patients were IPF patients
[46]. Despite testing positive, none of these five patients
exhibited symptoms of HCMV disease, suggesting that
viral infections in this population can be occult. The
increased incidence of HCMV infection prior to transplant
correlated with an increased risk of HCMV infection post-
transplant as well. In sum, there is evidence that suggests
an association between the incidence of HCMV infection
and the incidence of IPF, but a mechanism by which
HCMV may affect fibrosis remains to be elucidated.
Epstein-Barr virus
The virus that has been associated most strongly with IPF
is EBV. EBV is a gammaherpesvirus that is present in all
populations, infecting more than 95% of humans within
the first decades of life [47]. An association between EBV
infection and IPF was first established when elevated lev-
els of immunoglobulins A and G against EBV antigens
were measured in a serological study of 13 patients with
IPF [48]. In contrast, 12 patients with interstitial lung dis-
ease of known cause had normal EBV serological profiles.
This finding led to further research on EBV in the context
of IPF. An immunohistochemical study indicated that
EBV replicates within epithelial cells of the lower respira-
tory tract in IPF patients [49]. Consequently, Stewart et al.
[50] sought to confirm the presence of EBV DNA in the
lung tissue of IPF patients using PCR. They found that EBV
was present in the lungs of patients with IPF at a signifi-Page 3 of 11
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trol subjects (14%).
A couple of studies have associated the presence of active
and latent EBV markers with IPF. Kelly et al. [51] investi-
gated the occurrence of productive EBV replication by
analyzing for the presence of an EBV gene rearrangement
termed WZhet; 61% of EBV DNA-postive lung tissue biop-
sies from IPF patients were positive for WZhet. Buffy coat
analysis for WZhet was positive in 16 of 27 IPF patients
compared to none of 32 lung transplant recipients and 1
of 24 normal blood donors. Tsukamoto et al. [52] then
determined that the presence of EBV latent membrane
protein 1 (LMP1) is linked with more rapid disease pro-
gression. From a group of 29 patients, they found that
patients positive for LMP1 died more quickly than
patients who tested negative for EBV.
It should be noted that not all studies have found an asso-
ciation between EBV and IPF. In 1997, Wangoo et al. [53]
published findings contrary to previous reports when they
did not detect any EBV DNA in the lungs of IPF patients.
Also, in 2005, an Italian study by Zamo et al. [54] failed to
find evidence of either EBV or human herpesvirus (HHV)-
8 DNA in their tissue banks of IPF samples. Whether these
discrepancies reflect geographical distribution, technical
sensitivities, or disease heterogeneity is still unclear.
Although EBV had been detected with more frequency in
the lungs of IPF patients than in the lungs of control
patients in most previous studies, many members of each
IPF cohort analyzed did not test positive for EBV infection
at all. Tang et al. [45] went on to test the hypothesis that
at least one herpesvirus could be detected in the lungs of
all IPF patients. They identified one or more of four her-
pesviruses – EBV, HCMV, HHV-7, and HHV-8 – in 32 of
33 patients with IPF and in 9 of 25 controls. They found
two or more herpesviruses in 19 of 33 IPF patients and in
2 of 25 controls. These data strongly support the notion
that at least one herpesviral infection accompanies the
development of IPF.
Tang et al. drew other conclusions from their study that
suggest susceptibility to viral infection and IPF depends
on a genetic or acquired predisposition. Co-infection
occurred more frequently in patients with the sporadic
form of IPF compared to those with the familial form.
Familial IPF is characterized by the incidence of IPF in two
or more members of an immediate family [55]. This led
the authors to suggest that a patient with familial IPF may
require less viral influence to trigger a progressive fibrotic
response than a patient with sporadic IPF. In addition,
Tang et al. note that the increased frequency of HHV-8 in
the lungs of the IPF cohort is particularly interesting. In
the United States, HHV-8 infection is predominantly
found in patients with HIV infection and Kaposi's sar-
coma [56], and all of the subjects tested negative for HIV
in this study.
Collectively, the analyses of IPF lung tissue chronicled
above create a rationale to study the association between
viral infections and the occurrence of IPF, but do not pro-
vide evidence for a causal relationship between viruses
and IPF. Demonstrating causation in humans requires
detection of a virus in the lungs prior to clinical manifes-
tations of IPF (which is clinically implausible) or evidence
that an anti-viral therapy confers anti-fibrotic effects. The
latter has been attempted with some success in a limited
number of case studies, but no large trials have been con-
ducted to date [45,57]. While at least four different viruses
have been correlated with IPF, the most striking observa-
tions have linked EBV infection of lung tissue with the
presence of IPF. However, we want to again stress that the
pathogenesis of IPF is complex and multifactorial. In real-
ity, IPF is likely a spectrum of diseases that result from a
variety of genetic abnormalities and/or environmental
factors. As mentioned above, the data regarding the asso-
ciation of viruses, even EBV, with IPF are controversial.
What is particularly intriguing to us, however, is that these
clinical observations are somewhat strengthened by
emerging evidence in animal models that demonstrate
that gammaherpesvirus infections can be linked to the
development or the exacerbation of experimentally
induced fibrosis. These animal studies will be highlighted
below.
Animal studies that support a role for gammaherpesvirus 
infections as initiators or co-factors for the development of 
fibrosis
Naturally occurring cases of gammaherpesvirus infection and fibrosis
Pulmonary fibrosis has been reported to occur in both
cats and horses [58-62]. Interestingly, recent studies of
both horses and a single donkey have reported pulmonary
interstitial fibrosis associated with herpesvirus-associated
pneumonia [59,63]. It is interesting to note that infection
with equine herpesvirus-5, a gammaherpesvirus, was
detected by PCR in 19/24 (79.2%) horses affected with
interstitial fibrosis whereas only 2/23 (8.7%) of control
horses showed evidence of infection [59]. While these
data do not prove causality, the association between gam-
maherpesviruses and fibrosis in both horses and humans
is striking.
Murine modeling to demonstrate a causal role for 
gammaherpesvirus infection in the augmentation of fibrosis
Murine models of pulmonary fibrosis have enabled iden-
tification of pathogenic cells and mediators that are
believed to be important in human fibrotic disease, and
they have facilitated further exploration of a pathogenic
role for viruses in humans [64]. The human herpesvirusesPage 4 of 11
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infection capability in mice, however. Thus, investigators
have utilized a natural murine pathogen called murine
gammaherpesvirus (MHV)-68 that has been characterized
as genetically and biologically closely related to human
gammaherpesviruses. The genome of MHV-68 is largely
colinear with EBV and HHV-8, and there is evidence that
both murine and human gammaherpesviruses infect the
respiratory tract and can persist in B cells as well as lung
epithelial cells [65-69].
MHV-68 infection prior to bleomycin administration worsens fibrosis
In 2002, Lok et al. [70] used MHV-68 to demonstrate that
gammaherpesviruses could serve as a cofactor in the
development of pulmonary fibrosis. BALB/c mice infected
intranasally with MHV-68 one week prior to intratracheal
administration with the fibrotic stimulant bleomycin later
developed pulmonary fibrosis even though BALB/c mice
are normally resistant to bleomycin. Mice infected with
MHV-68 but not challenged with bleomycin did not
develop fibrosis. The gammaherpesvirus infection alone
was not sufficient to cause fibrosis, but Lok et al. proposed
that a viral infection made the previously protected lungs
susceptible to fibrotic disease upon the event of an exoge-
nous injury. These results are enticing, but it should be
noted that the bleomycin was delivered during the peak of
lytic viral infection. It is difficult to infer from these stud-
ies whether chronic latent infection with MHV-68 might
also predispose the lung to subsequent fibrotic responses.
Also, the mechanism(s) for how MHV-68 infection aug-
mented the subsequent fibrotic response to bleomycin
were not defined. This is an area of active research in our
laboratory. We have determined that MHV-68 infection is
latent in the lung by day 14 post-infection [42]. Mice
given MHV-68 14 days prior to the administration of ble-
omycin and harvested 21 days post-bleomcyin show a dif-
ferent pattern of inflammation and fibrosis than is noted
in mice mock infected prior to bleomycin administration
(Figure 1). Of note, focal clusters of mononuclear inflam-
matory leukocytes are seen in the setting of viral infection.
Thus, it is likely that latent viral infections alter the inflam-
matory response that occurs in response to a secondary
fibrotic stimulus.
MHV-68 infection in Th2-biased mice causes multi-organ fibrosis
Ebrahimi et al. [71] showed that MHV-68 causes fibrosis
in interferon (IFN)γR-/- mice. IFN-γ is a Th1 cytokine with
anti-viral and anti-fibrogenic properties. It down-regu-
lates the expression of both type I and type III collagens
and fibronectin [72-75]. The cytokine profile of IFNγR-/-
mice is Th2-biased, resulting in a cytokine imbalance sim-
ilar to that observed in the lungs of IPF patients [76]. This
study suggests that a herpesvirus infection delivered to
lungs skewed towards a profibrotic cytokine environment
is sufficient for fibrogenesis. In this case, the fibrogenesis
was not limited to the lung only. The mice developed
multi-organ fibrosis (liver, lung, spleen and lymph
nodes). The development of multi-organ fibrosis corre-
lated with an overproduction of pro-fibrotic mediators
such as TNF-α, TNF-β, IL-1β, TGF-β1, lymphotactin, and
macrophage inflammatory protein-1β (MIP-1β). These
mediators were elevated on day 14 after infection whereas
the anti-fibrotic chemokines CXCL9 (CXC chemokine lig-
and 9) and CXCL10 were significantly reduced. The
authors noted that MHV-68 gene expression may have
influenced the cytokine imbalance. These results are fasci-
nating in light of the fact that MHV-68 infection in wild-
type mice shows no signs of causing multi-organ fibrosis
and suggest that the outcome of viral infection may be
critically dependent on the cytokine milieu at the time of
infection.
Herpesviral infections change the nature of the inflammatory response to subsequent fibrotic stim liFigure 1
Herpesviral infections change the nature of the inflammatory 
response to subsequent fibrotic stimuli. Mice were given 5 × 
104 pfu MHV-68 or saline 14 days prior to the instillation of 
bleomycin as a fibrotic stimulus. Mice were euthanized and 
lungs were prepared for histology 21 days post-bleomycin. 
Panels on the left-hand side represent mice pre-treated with 
saline, and then challenged with bleomcyin. Panels on the 
right-hand side represent mice infected with MHV-68 prior 
to the bleomcyin challenge. MHV-68 was latent at the time of 
bleomycin inoculation. Viral pre-infection causes increased 
numbers of inflammatory cells to enter the lung during the 
subsequent fibrotic response. We have verified this with col-
lagenase digests and cell counts as well (not shown). It is par-
ticularly interesting that the virally infected mice show focal 
clusters of mononuclear cells (yellow arrows) that are not 
seen in the mice challenged with bleomycin alone. The inset 
in the lower right panel is a 1,000× magnification of one of 
these mononuclear foci. Based on morphology, these cells 
are likely leukocytes.Page 5 of 11
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herpesvirus-induced fibrosis by characterizing the disease
seen in the lungs and examining possible pathogenic
effects of the virus that contribute to fibrosis. They showed
that MHV-68 induces epithelial damage and inflamma-
tory responses leading to alveolar remodeling and ulti-
mately to unresolving progressive interstitial fibrosis
resembling human IPF. More recently, Mora et al. [77]
published data implicating alveolar macrophages as inte-
gral profibrotic effectors in IFNγR-/- mice. These studies
suggested that alveolar macrophages were chronically
recruited to areas of epithelial hyperplasia and fibrosis
and that these alveolar macrophages displayed signs of
alternative activation, a process known to be driven by
Th2 cytokines. The alternatively activated macrophages
express arginase. Arginase metabolism of L-arginine to L-
ornithine, L-proline, and polyamine promotes fibroblast
proliferation, collagen production, and, ultimately, fibro-
sis. In addition, there is evidence that microvascular injury
has a role in the pathogenesis of IPF [78], and Mora et al.
[57] detected viral-induced vasculitis accompanied by red
blood cell extravasation compatible with hemorrhage.
With regards to viral-induced vasculitis, it is interesting
that Magro et al. [78], who proposed microvascular injury
as a pathogenic mechanism for IPF, also found evidence
of CMV and parvovirus B19 infection in IPF patients. In
fact, Magro et al. [78] speculated that endotheliotropic
viral infections, such as CMV and B19, may be precursors
for the microvascular injury that is noted in IPF [78]. Sim-
ilar mechanisms may be responsible for the MHV-68-
induced damage noted in the studies by Mora et al. MHV-
68 has previously been reported to cause vascular damage
[79]. Finally, Mora et al. [57] noted enhanced expression
of the profibrotic cytokine TGF-β1 in the MHV-68-
infected IFNγR-/- mice, and it is likely that this pro-fibrotic
cytokine may make a significant contribution to the fibro-
sis in this model. In wild-type mice, however, IFN-γ sign-
aling would be expected to inhibit transcription of the
TGF-β gene [80].
The authors attribute some of the TGF-β1 dysregulation to
epithelial cell damage. Interestingly, type II alveolar cells
are a target of MHV-68, and Mora et al. [57] speculate that
epithelial cell infection and injury may be triggering sur-
factant abnormalities as well as dysregulated epithelial
cell repair. An association between the frequency of poly-
morphic variants of surfactants and IPF has been docu-
mented previously [81]. Furthermore, another series of
studies on IPF has found some evidence that a link
between EBV and p53 expression leads to modifications
in epithelial cell repair and apoptosis [82,83]. Flano et al.
[84] have reported chronic low level reactivation of MHV-
68 in the lung. It is possible that reactivation is a repetitive
trigger in the setting of the IFNγR-/- mice that contributes
to the progressive disruption of lung epithelial cells and
unresolving fibrosis. In support of this, preventing
chronic reactivation of MHV-68 to the lytic phase through
the use of anti-viral drugs reduces fibrosis in IFN-γR-/-
mice [84,85]. Table 1 summarizes potential mechanisms
whereby preceding viral infection may predispose the
host to the development of fibrosis.
MHV-68 as an exacerbating agent for established fibrosis
While most IPF patients have a slow, progressive disease,
some patients have an acute deterioration in function that
carries a poor prognosis. In the placebo arm of a study of
32 patients who died from IPF-related causes, Martinez et
al. [86] reported that 47% suffered an acute deterioration,
and 27% of the acute deteriorations were associated with
infection. We were recently able to model acute exacerba-
tions of fibrosis in a murine model of FITC-induced pul-
monary fibrosis. Wild-type mice infected with MHV-68
after the establishment of fibrosis (day 14) developed a
significantly worse fibrotic response than fibrotic mice
that were mock-infected with saline [42]. This finding is
especially interesting in light of the work done in Th2-
biased mice discussed above because MHV-68 exacerba-
tion of fibrosis in wild-type mice occurred despite a strong
Th1-biased anti-viral immune response. In fact, MHV-68
was able to exacerbate FITC-induced fibrosis even in Th2-
deficient (IL-4 and IL-13-/-) mice [42]. In these experi-
ments looking at exacerbation of established fibrosis,
MHV-68 infection was lytic. The pro-fibrotic actions of
MHV-68 may vary greatly depending on whether the
Table 1: Potential mechanisms to explain how viral infections may predispose the host to develop fibrosis
Lytic infections may kill lung epithelial cells
Latent infections may alter the phenotype 
(proliferation, apoptosis or mediator secretion) of various lung cells (for example, epithelial and mesenchymal cells)
Persistent viruses may provide repeated insults with reactivation
Infection may increase the production of pro-fibrotic mediators (for example, TGF-β) or diminish the production of anti-fibrotic mediators
Induction of epithelial to mesenchymal transition
Induction of chemokines and fibrocyte recruitment
Surfactant abnormalities
Enhanced inflammation
Alteration of p53 function
Microvascular injuryPage 6 of 11
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the contribution of Th2 cytokines to the pathogenesis
may vary as well depending on the timing of infection.
The recruitment of fibrocytes to the lung was also associ-
ated with viral exacerbation of FITC-induced fibrosis [42].
Fibrocytes are bone marrow-derived cells that share the
characteristics of both leukocytes and mesenchymal cells
and are defined by the co-expression of CD45 and colla-
gen 1 [17]. Fibrocytes migrate in response to chemokine
signals and likely contribute to fibrogenesis both via dif-
ferentiation into myofibroblasts as well as through the
paracrine secretion of pro-fibrotic mediators [18,19,87-
89]. If MHV-68 infection is able to recruit fibrocytes, then
this mechanism may be able to explain the enhancement
of fibrosis noted by Lok et al. [70] when the infection pre-
ceded the administration of bleomycin by 7 days. In fact,
if MHV-68 infection in the lung is associated with pro-
longed recruitment of fibrocytes even after the virus has
established latency, this could explain why herpesviral
infections may predispose persons to an enhanced fibrotic
response upon a second challenge. It may also explain, in
part, the altered inflammatory responses noted when
mice latently infected with MHV-68 are challenged with a
fibrotic stimulus (Figure 1). We have gathered preliminary
data in our lab that suggest that fibrocyte accumulation in
the lung is elevated for at least 30 days post-MHV-68
infection (unpublished observation). Thus, this will be an
area of active future exploration. It is likely that viral infec-
tions alter epithelial cell function, cytokine profiles and
inflammatory cell accumulation to promote fibrosis.
Table 2 summarizes potential mechanisms to explain the
ability of a viral infection to exacerbate existing pulmo-
nary fibrosis.
Conclusion
The studies with MHV-68 discussed here can only suggest
that similar human viruses found in the lungs of IPF
patients have a pathogenic role in fibrosis. Given that
fibrosis in humans is progressive, it seems important to
better understand the chronic reactivation that can occur
during herpesviral infections. It is possible that repeated
activation may lead to repeated rounds of epithelial cell
damage, cytokine release and fibrocyte recruitment. Addi-
tionally, it will be important to determine whether long-
term latent MHV-68 infection of naïve mice augments the
production of profibrotic factors and whether the same is
true in EBV-infected human lungs. A latent infection does
not appear to create a Th2 bias equal to that of IFN-γR-/-
mice, but any bias may predispose a latently infected indi-
vidual to a fibrotic trigger from an unrelated factor. It will
also be helpful to more carefully study the cell types that
harbor long-standing viral infection because the pro-
longed injury caused to such a cell type is likely responsi-
ble for increasing susceptibility to fibrosis. Flano et al. [84]
found that long-term latency in the lung is maintained
primarily in B cells, but they also showed that MHV-68
maintains persistent replication in the lung at least 3
months after infection, suggesting that cell types besides B
cells may be re-infected. In fact, Stewart et al. [68] have
suggested that lung epithelial cells may be long-term res-
ervoirs of persistent viral infection. Epigenetic changes
caused by infection should also be explored. Genetic defi-
ciencies in leukotriene production and expression of the
CCR2 receptor have been shown to be protective against
fibrosis in animal models independent of viral infection
[90,91]. As viral infections are known to induce the pro-
duction of both leukotrienes and chemokines, it may be
important to understand how significant such mediators
are to a virus-induced predisposition to fibrosis. It is also
possible that the additional inflammatory cells recruited
by the lytic or latent virus may alter the fibrotic milieu. In
summary, evidence from both clinical studies and animal
models suggest that viruses, especially gammaherpesvi-
ruses, may be co-factors for the development or exacerba-
tion of lung fibrosis and have suggested that fibrocyte
recruitment may be one pathogenic mechanism. Figure 2
provides a schematic representation that depicts potential
mechanisms whereby viral infections (either preceding
the fibrotic response or subsequent to it) may enhance
fibrotic outcomes. Through the use of new animal mod-
els, researchers should be able to elucidate additional
pathogenic mechanisms with the hope of finding new
therapies.
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Schematic representation depicting potential mechanisms involved in viral augmentation of fibrosisFigure 2
Schematic representation depicting potential mechanisms involved in viral augmentation of fibrosis. Viral infection may precede 
the fibrotic insult or occur subsequent to the fibrotic challenge. In both cases, recruitment of inflammatory cells, including 
fibrocytes, increases in pro-fibrotic mediator production and epithelial cell injury may play important roles.
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